20 results
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
29 Apr 24
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
6:30am
development, and to our dedicated employees for making this targeted breakthrough therapy a reality.”
“Effective and innovative treatments … by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
29 Apr 24
Regulation FD Disclosure
8:30am
product launch
18 The right field team to launch an innovative rare disease medicine Mission-driven, patient-centric: bringing a novel therapy … indicated for WHIM syndrome Committed to Providing Innovative Solutions Dedicated support and education available through X4Connect and PANTHERx Rare
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
27 Nov 19
X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class B Warrants
5:18pm
the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
9 May 24
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105
6:58am
innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system
8-K
EX-99.2
XFOR
X4 Pharmaceuticals Inc
27 Nov 19
X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class B Warrants
5:18pm
and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4
8-K
EX-99.2
cr48 gxreragyxx1t
3 Nov 22
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:21am
8-K
EX-99.1
douobel6 yfpfebb
7 May 24
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
6:28am
8-K
EX-99.1
tvie6jveuafrc
26 Jun 19
Other Events
8:44am
8-K
EX-99.1
oihspw0p8 cfv
30 Sep 19
Subgroup exceeds target of 50% improvement in median progression-free survival
7:21am
8-K
EX-99.1
e04syyv0zp4 lgz46tv
3 Nov 22
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:21am
8-K
EX-99.1
bvbsagzknifgvtpz7fi
7 Nov 19
X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights
7:10am
8-K
EX-99.1
8xc2xdip36ppx6r4f
5 Aug 22
Regulation FD Disclosure
8:10am
ARS
hfbu0tk
29 Apr 24
Annual report to shareholders
4:58pm
10-K
e7gkwi
9 Mar 18
Annual report
12:00am
- Prev
- 1
- Next